KRT18-affected FGF21 was reported to activate the FGF signaling pathway by binding FGFR and have therapeutic potential in GC as a diagnostic and prognostic biomarker (Degirolamo et al., 2016; Zhang et al., 2019b). The gene discussed is FGF21; the disease is gastric cancer.